Filtered By:
Specialty: Dermatology
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 964 results found since Jan 2013.
Safety and Efficacy of TGF- β1/COX-2 Silencing Therapeutic in Adults With Cutaneous Squamous Cell Carcinoma In Situ
J Drugs Dermatol. 2022 May 1;21(5):472-477. doi: 10.36849/JDD.6384.ABSTRACTThis single-center, open label, dose escalation cohort study evaluated the safety and efficacy of various doses of intralesional injections of TGF-β1/COX-2 combined with histidine-lysine polypeptide (siRNA/HKP) nanoparticle silencing therapeutic in patients with cutaneous in situ squamous cell carcinoma. Twenty-five patients (mean age: 67, SD: 10 years; 52% men) with cutaneous in situ squamous cell carcinoma participated. TGF-β1/COX-2 siRNA/HKP nanoparticle therapeutic was injected weekly for up to 6 weeks based on the following do...
Source: Journal of Drugs in Dermatology - May 9, 2022 Category: Dermatology Authors: Mark Nestor Brian Berman Patrick Lu Michael Molyneaux Source Type: research
Knockdown of CPEB1 and CPEB4 Inhibits Scar Formation via Modulation of TAK1 and SMAD Signaling
CONCLUSION: CPEB1 siRNA or CPEB4 siRNA inhibit scar formation by modulating the TAK1 and SMAD signaling pathways. Our study highlights CPEB1 and CPEB4 as potential therapeutic targets for the treatment of scar formation.PMID:37550230 | DOI:10.5021/ad.22.210
Source: Annals of Dermatology - August 7, 2023 Category: Dermatology Authors: Hui Song Cui You Ra Lee Yu Mi Ro So Young Joo Yoon Soo Cho June-Bum Kim Dong Hyun Kim Cheong Hoon Seo Source Type: research
